DaVita Inc. stock holds recent gains on strong Q2 2026 results and EPS guidance

DaVita Inc. stock (ISIN US23918K1088) is trading around USD 183 on the New York Stock Exchange after the kidney care provider delivered stronger Q2 2026 figures, with earnings per share of USD 4.02 and revenue rising 5.2 percent year over year to USD 3.55 billion as of September 19, 2026, according to MarketBeat.

Q2 2026 results beat expectations

According to MarketBeat on September 19, 2026, DaVita reported Q2 2026 earnings per share of USD 4.02, beating analyst estimates of USD 3.88 by USD 0.14 in the period ended June 30, 2026.

In the same Q2 2026 quarter, DaVita’s revenue rose 5.2 percent year over year to USD 3.55 billion, illustrating mid-single-digit top-line growth in its kidney care operations compared with the prior-year period, as highlighted by MarketBeat.

For investors, the combination of an EPS beat and revenue growth above inflation is an important signal that DaVita is managing reimbursement pressures and cost inflation effectively in its core dialysis business, even as the broader healthcare sector faces margin headwinds.

Guidance for FY 2026 EPS supports valuation

Beyond the Q2 2026 numbers, DaVita has set its guidance for fiscal year 2026 earnings per share in a range between USD 14.10 and USD 15.20, giving the market a relatively tight corridor for the full-year profit outlook, according to MarketBeat.

This guidance range implies that, if DaVita delivers at the midpoint of about USD 14.65 per share in FY 2026, earnings would represent solid double-digit growth compared with historical levels and underpin the current valuation around the USD 183 mark as of mid-September 2026.

Analyst consensus reflects this constructive view: the same overview from MarketBeat indicates that DaVita has an average rating score of 2.57 on its scale, based on 4 buy ratings and 3 hold ratings, with a consensus price target of USD 233.43.

At a recent share price of USD 183.59, that consensus target suggests implied upside of around USD 49.84 per share, or roughly 27.1 percent relative to the current level, as summarized by MarketBeat.

Stock near the middle of its 52-week range

DaVita stock trades on the New York Stock Exchange under the ticker DVA, giving it access to deep liquidity among U.S. healthcare investors, and the reference price for the current assessment is the NYSE level of USD 183.59 on September 18, 2026 in U.S. dollars, according to data cited by MarketBeat.

The same source notes that DaVita’s market capitalization stood around USD 11.71 billion at that price as of September 18, 2026, placing the company in the low-double-digit billion range among U.S. health care providers and services peers based on equity value.

MarketBeat data also indicate that DaVita shares are trading within a quantified twelve-month band between a 52-week low of USD 101.00 and a 52-week high of USD 247.49, meaning the current level near USD 183.59 sits well above the low but still clearly below the high, giving investors both an illustration of past volatility and the remaining gap to previous peaks.

Short interest and risk considerations

Short interest figures provide another lens on sentiment: as of August 31, 2026, DaVita had 4.68 million shares sold short, representing 7.47 percent of the public float, according to MarketBeat.

While a short interest near 7.47 percent is not extreme in absolute terms, it suggests a meaningful minority of market participants remain cautious about DaVita’s ability to sustain its current earnings trajectory and valuation, especially given the regulatory and reimbursement risks in the U.S. kidney-care market.

For long-term investors, the key question is whether the company’s operational execution in Q2 2026 and its FY 2026 EPS guidance can continue to offset these risks; the existing spread between the current price and the consensus target reflects that the market is still pricing in some uncertainty despite the recent beats.

DaVita Inc. stock price and trading data

As of the most recent completed trading day referenced in the available overviews, DaVita Inc. stock closed around USD 183.59 on the New York Stock Exchange on September 18, 2026, with intraday indications also clustered around USD 183.86 in snapshots taken on September 19, 2026 in U.S. dollars.

At that level, DaVita’s equity is valued at approximately USD 11.71 billion based on the NYSE quotation as of September 18, 2026, and the shares remain significantly above the 52-week low of USD 101.00 while trading below the 52-week high of USD 247.49 mentioned in the MarketBeat data for the same period.

For investors watching the chart, this positioning near the middle of the annual trading range means DaVita Inc. stock still has room to retest its previous highs if the company continues to deliver on its FY 2026 EPS guidance and the broader health care sector backdrop remains supportive, but it also underscores the sensitivity of the shares to any disappointment on margins or regulatory developments.

More news and analyses on DaVita Inc. stock